{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:29:59Z","timestamp":1787315399910,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clgc.2024.102282","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T12:11:11Z","timestamp":1732882271000},"page":"102282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8659-7327","authenticated-orcid":false,"given":"Hatice","family":"B\u00f6lek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Sertesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer Faruk","family":"Kuzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2144-6469","authenticated-orcid":false,"given":"Deniz","family":"Tural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadet","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali Nahit","family":"\u015eendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7649-1075","authenticated-orcid":false,"given":"G\u00f6khan","family":"U\u00e7ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2726-1740","authenticated-orcid":false,"given":"Selver","family":"I\u015f\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8490-3239","authenticated-orcid":false,"given":"Bekir","family":"Hac\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130rfan","family":"\u00c7i\u00e7in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-7432","authenticated-orcid":false,"given":"\u00c7a\u011fatay","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema Sezgin","family":"G\u00f6ksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3462-9360","authenticated-orcid":false,"given":"\u00d6zlem Nuray","family":"Sever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cengiz","family":"Kara\u00e7in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuri","family":"Karadurmu\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u00d6zg\u00fcro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Yeked\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-9887","authenticated-orcid":false,"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2024.102282_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: a cancer journal for clinicians"},{"key":"10.1016\/j.clgc.2024.102282_bib0002","unstructured":"Cancer Stat Facts: Kidney and Renal Pelvis Cancer [Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html (Accessed July 02, 2024)."},{"issue":"19","key":"10.1016\/j.clgc.2024.102282_bib0003","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"New Eng J Med"},{"issue":"11","key":"10.1016\/j.clgc.2024.102282_bib0004","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clgc.2024.102282_bib0005","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2024.102282_bib0006","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102282_bib0007","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102282_bib0008","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2024.102282_bib0009","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"New Eng J Med"},{"key":"10.1016\/j.clgc.2024.102282_bib0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2024.102282_bib0011","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102282_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101210","article-title":"Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma","volume":"8","author":"Haanen","year":"2023","journal-title":"ESMO open"},{"key":"10.1016\/j.clgc.2024.102282_bib0013","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1200\/EDBK_155975","article-title":"Access to cancer therapeutics in low-and middle-income countries","volume":"36","author":"Ruff","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.clgc.2024.102282_bib0014","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JOP.2015.004929","article-title":"Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice","volume":"11","author":"Mitchell","year":"2015","journal-title":"J Oncol Prac"},{"issue":"12","key":"10.1016\/j.clgc.2024.102282_bib0015","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1093\/annonc\/mdt397","article-title":"Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials","volume":"24","author":"Templeton","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102282_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.11329","article-title":"Real-world survival outcomes associated with first-line immunotherapy, targeted therapy, and combination therapy for metastatic clear cell renal cell carcinoma","volume":"4","author":"Chakiryan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2024.102282_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4117-z","article-title":"Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data","volume":"18","author":"Maroun","year":"2018","journal-title":"BMC Cancer"},{"issue":"3\u20134","key":"10.1016\/j.clgc.2024.102282_bib0018","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminoncol.2024.02.002","article-title":"Reno study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain","volume":"51","author":"Badiola","year":"2024","journal-title":"Sem Oncol;"},{"key":"10.1016\/j.clgc.2024.102282_bib0019","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.euros.2022.12.015","article-title":"Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era","volume":"49","author":"Shah","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2024.102282_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.803935","article-title":"Real-world metastatic renal cell carcinoma treatment patterns and clinical outcomes in The Netherlands","volume":"13","author":"van Laar","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102282_bib0021","article-title":"Treatment patterns and attrition with lines of therapy for advanced urothelial carcinoma in the US","volume":"7","author":"Thomas","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"Suppl. 1","key":"10.1016\/j.clgc.2024.102282_bib0022","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000530416","article-title":"The cancer treatment gap in lower-to middle-income countries","volume":"101","author":"Cardone","year":"2023","journal-title":"Oncology"},{"key":"10.1016\/j.clgc.2024.102282_bib0023","article-title":"Availability, affordability, access, and pricing of anti-cancer medicines in low-and middle-income countries: a systematic review of literature","volume":"9","author":"Ocran Mattila","year":"2021","journal-title":"Front Pub Health"},{"issue":"10","key":"10.1016\/j.clgc.2024.102282_bib0024","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102282_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102994","article-title":"Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial","volume":"9","author":"Powles","year":"2024","journal-title":"ESMO open"},{"issue":"11","key":"10.1016\/j.clgc.2024.102282_bib0026","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of clear, a phase III study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102282_bib0027","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1200\/JCO.2023.41.6_suppl.603","article-title":"Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial","volume":"41","author":"Burotto","year":"2023","journal-title":"Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102282_bib0028","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/annonc\/mdv504","article-title":"Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry","volume":"27","author":"Wagstaff","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2024.102282_bib0029","first-page":"1","article-title":"Assessment of treatment patterns for metastatic renal cell carcinoma in Brazil","volume":"4","author":"Bergerot","year":"2017","journal-title":"J Global Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102282_bib0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3233\/KCA-170020","article-title":"Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC)","volume":"2","author":"Stukalin","year":"2018","journal-title":"Kidney Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324002520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T15:20:47Z","timestamp":1753111247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324002520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1558767324002520"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102282","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102282"}}